Categories: News

Veeva to Release Fiscal 2022 Fourth Quarter and Full Year Results on March 2, 2022

PLEASANTON, Calif., Feb. 1, 2022 /PRNewswire/ — Veeva Systems (NYSE: VEEV) will announce financial results for its fourth quarter and full fiscal year, which ended January 31, 2022, after market close on March 2, 2022. Veeva will host a conference call and webcast that day at 2:00 p.m. PT (5:00 p.m. ET) to discuss its financial results.

Veeva will post prepared remarks to its investor relations website at https://ir.veeva.com approximately at 1:05 p.m. PT (4:05 p.m. ET). A webcast replay will be available on the website following the live event.

Event:              Veeva’s Fiscal 2022 Fourth Quarter and Full Year Results Conference Call

Date:                Wednesday, March 2, 2022

Time:               2:00 p.m. PT (5:00 p.m. ET)

Online Registration: www.directeventreg.com

Conference ID: 86021

Webcast:          ir.veeva.com

About Veeva Systems
Veeva is the global leader in cloud software for the life sciences industry. Committed to innovation, product excellence, and customer success, Veeva serves more than 1,000 customers, ranging from the world’s largest pharmaceutical companies to emerging biotechs. As a Public Benefit Corporation, Veeva is committed to balancing the interests of all stakeholders, including customers, employees, shareholders, and the industries it serves. For more information, visit veeva.com.

Veeva uses its ir.veeva.com website as a means of disclosing material non-public information, announcing upcoming investor conferences, and for complying with its disclosure obligations under Regulation FD. Accordingly, you should monitor Veeva’s investor relations website in addition to following its press releases, SEC filings, and public conference calls and webcasts.

 

View original content:https://www.prnewswire.com/news-releases/veeva-to-release-fiscal-2022-fourth-quarter-and-full-year-results-on-march-2-2022-301473046.html

SOURCE Veeva Systems

Staff

Recent Posts

Pentixapharm Announces Peer-Reviewed Phase 2 Data Back Use of PENTIXAFOR as a Superior Non-invasive PET-Diagnostic for Primary Aldosteronism

In the study, [68Ga]Ga-Pentixafor PET/CT was well tolerated and demonstrated high specificity and moderate sensitivity…

10 minutes ago

Introduction of Connected Care for Canadians Act

TORONTO, Feb. 4, 2026 /CNW/ - Canada Health Infoway (Infoway) welcomed today's introduction of Bill S-5, the…

9 hours ago

Introduction of Connected Care for Canadians Act

TORONTO, Feb. 4, 2026 /CNW/ - Canada Health Infoway (Infoway) welcomed today's introduction of Bill S-5, the…

9 hours ago

In HelloNation, Occupational Health Expert Kat Parmer of Cheyenne, WY, Shares a Guide for Effective Pre-Employment Screenings

CHEYENNE, Wyo., Feb. 4, 2026 /PRNewswire/ -- How can Wyoming employers ensure that new hires…

9 hours ago

In HelloNation, Occupational Health Expert Kat Parmer of Cheyenne, WY, Shares a Guide for Effective Pre-Employment Screenings

CHEYENNE, Wyo., Feb. 4, 2026 /PRNewswire/ -- How can Wyoming employers ensure that new hires…

9 hours ago

Candid Health Named to the 2026 New York Digital Health 100

DH100 recognizes the companies shaping the future of healthcare innovation in NY, spotlighting Candid's role…

9 hours ago